The National clinical practice guidelines on the management of opiod use disorders were developed in accordance with the highest international guideline development standards, and was reviewed and developed by over 40 members of the national guideline development committee. The goals of this guideline are to provide an essential resource to healthcare providers in learning how to manage opioid use disorders and to encourage a greater cohesion and standardization of medical practice, with a hope that these recommendations will be adopted and distributed by relevant regulatory and professional bodies across Canada. This guideline includes two companion documents: a clinical guideline and an operational guidance document.

National Injectable Opioid Agonist Treatment for Opioid Use Disorder Operational Guidance

Canadian Research Initiative in Substance Misuse (CRISM).

National Injectable Opioid Agonist Treatment for Opioid Use Disorder Clinical Guideline.
Canadian Research Initiative in Substance Misuse (CRISM)

The Lower-risk Cannabis use guidelines (LRCUG) have received authoritative national endorsements from six leading national medical, public health, and substance use organizations: Canadian Medical Association (CMA), Canadian Public Health Association (CPHA), Council of Chief Medical Officers of Health (in principle) (CCMOH), Canadian Society of Addiction Medicine (CSAM), Canadian Centre on Substance Use and Addiction (CCSA), and Centre for Addiction and Mental Health (CAMH).

Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations.
Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, Rehm J, Room R.

Start typing and press Enter to search